The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy

xlomafota13 shared this article with you from Inoreader The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy Via American Journal of Cancer Research Am J Cancer Res. 2022 Feb 15;12(2):681-694. eCollection 2022. ABSTRACT Ovarian cancer is a relatively common tumor in women with the highest mortality among female reproductive system tumors. The lack of apparent early symptoms and effective screening strategies often leads to ovarian cancer being diagnosed at an advanced stage. Immunotherapy relying on tumor-associated antigens might improve the treatment of ovarian cancer. Cancer-testis antigens (CTAs) are ideal tumor-associated antigens, and MAGE-A, NY-ESO-1, CT45, and Sp17 are classic CTAs highly expressed in ovarian cancer. Here, we review the research on CTAs in ovarian cancer, including prognostic value and advances in immunotherapy, all of which are essential for developing a theoretical basis for targeted therapy strategies. PMID:35261795 | PMC:PMC8899981 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.